Skip to main content

Advertisement

SpringerLink
Log in

Mild Cognitive Impairment: Current Aspects of Diagnosis and Treatment

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

This review addresses current published data on the diagnosis and treatment of mild cognitive impairment (MCI). MCI is not the normal accompaniment of aging but an intermediate state between normal cognitive status and mild dementia. The concept of MCI has developed actively over the last few decades, and significant amounts of knowledge and clinical experience have been acquired; numerous clinical trials have been conducted to develop effective methods for diagnosis and treatment. The treatment of predementia cognitive impairments is considerably different from the treatment for dementia and has a better prognosis, so diagnosis and initiation of treatment of cognitive impairments should be as early as possible. The main options for medication and nonmedication therapy are described, with the focus on the use of dopamine receptor agonist piribedil in the treatment of MCI and sensory defi cit in elderly patients. The mechanism of action of the drug is discussed and data from the main clinical trials of the effi cacy and safety of piribedil are presented: more than 10 international clinical trials involving around 7000 patients have demonstrated that the drug has positive effects on cognitive functions, as have a number of postmarketing studies in the Russian population of patients. Piribedil has been used successfully in various types of mild and moderate cognitive disorders of both neurodegenerative and vascular nature.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. N. Chehrehnegar, V. Nejati, M. Shati, et al., “Early detection of cognitive disturbances in mild cognitive impairment: a systematic review of observational studies,” Psychogeriatrics, 20, 212–228 (2020), https://doi.org/10.1111/psyg.12484.

    Article  PubMed  Google Scholar 

  2. R. C. Petersen, “Mild cognitive impairment,” Continuum (Minneap. Minn.), 22, 404–418 (2016), https://doi.org/10.1212/CON.0000000000000313.

    Article  Google Scholar 

  3. C. R. Jack, Jr, M. S. Albert, D. S. Knopman, et al., “Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease,” Alzheimers Dement., 7, No. 3, 257–262 (2011), https://doi.org/10.1016/j.jalz.2011.03.004.

    Article  PubMed  PubMed Central  Google Scholar 

  4. H. Chertkow, H. H. Feldman, C. Jacova, and F. Massoud, “Definitions of dementia and predementia states in Alzheimer’s disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia,” Alzheimers Res. Ther., 5, Supplement 1, S2 (2013), https://doi.org/10.1186/alzrt198.

  5. R. A. Sperling, P. S. Aisen, L. A. Beckett, et al., “Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease,” Alzheimers Dement., 7, No. 3, 280–292 (2011), https://doi.org/10.1016/j.jalz.2011.03.003.

    Article  PubMed  PubMed Central  Google Scholar 

  6. R. C. Petersen, “Mild cognitive impairment,” Continuum (Minneap. Minn.), 10, No. 1, Dementia, 9–28 (2004), https://doi.org/10.1212/01.CON.0000293545.39683.cc.

  7. M. S. Albert, S. T. DeKosky, D. Dickson, et al., “The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease,” Alzheimers Dement., 7, No. 3, 270–279 (2011), https://doi.org/10.1016/j.jalz.2011.03.008.

    Article  PubMed  PubMed Central  Google Scholar 

  8. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Publishing (2013), 5th ed.

  9. B. Dubois, H. H. Feldman, C. Jacova, et al., “Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria,” Lancet Neurol., 13, No. 6, 614–629 (2014), https://doi.org/10.1016/S1474-4422(14)70090-0.

    Article  PubMed  Google Scholar 

  10. O. Hansson, H. Zetterberg, P. Buchhave, et al., “Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study,” Lancet Neurol., 5, No. 3, 228–234 (2006), https://doi.org/10.1016/S1474-4422(06)70355-6.

    Article  CAS  PubMed  Google Scholar 

  11. K. A. Johnson, A. Schultz, R. A. Betensky, et al., “Tau positron emission tomographic imaging in aging and early Alzheimer disease,” Ann. Neurol., 79, No. 1, 110–119 (2016), https://doi.org/10.1002/ana.24546.

    Article  PubMed  Google Scholar 

  12. M. W. Weiner, D. P. Veitch, P. S. Aisen, et al., “Impact of the Alzheimer’s Disease Neuroimaging Initiative, 2004 to 2014,” Alzheimers Dement., 11, No. 7, 865–884 (2015), https://doi.org/10.1016/j.jalz.2015.04.005.

    Article  PubMed  PubMed Central  Google Scholar 

  13. B. Winblad, S. Gauthier, L. Scinto, et al., “Safety and efficacy of galantamine in subjects with mild cognitive impairment,” Neurology, 70, No. 22, 2024-2035 (2008), https://doi.org/10.1212/01.wnl.0000303815.69777.26.

    Article  CAS  PubMed  Google Scholar 

  14. H. H. Feldman, S. Ferris, B. Winblad, et al., “Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study,” Lancet Neurol., 6, No. 6, 501–512 (2007), https://doi.org/10.1016/S1474-4422(07)70109-6.

    Article  CAS  PubMed  Google Scholar 

  15. A. A. Pilipovich and A. B. Danilov, “New strategies for the diagnosis and treatment of Alzheimer’s disease: monoclonal antibodies to β-amyloid,” Med. Alfavit, No. 2, 35–42 (2019), https://doi.org/10.33667/2078-5631-2019-1-2(377)-35-42.

  16. J. Cummings, P. S. Aisen, B. DuBois, et al., “Drug development in Alzheimer’s disease: the path to 2025,” Alzheimers Res. Ther., 8, 39 (2016), https://doi.org/10.1186/s13195-016-0207-9.

    Article  PubMed  PubMed Central  Google Scholar 

  17. A. Barrera-Ocampo, and F. Lopera, “Amyloid-beta immunotherapy: the hope for Alzheimer disease?” Colomb. Med. (Cali), 47, No. 4, 203–212 (2016), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335861, acc. 09.25.2020.

  18. E. M. Reiman, J. B. Langbaum, A. S. Fleisher, et al., “Alzheimer’s Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments," J. Alzheimers Dis., 3, 321–329 (2011), https://doi.org/10.3233/JAD-2011-0059.

    Article  Google Scholar 

  19. N. Prins and P. Scheltens, “Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future,” Alzheimers Res. Ther., 5, No. 6, 56 (2013), https://doi.org/10.1186/alzrt220.

  20. J. Mendiola-Precoma, L. C. Berumen, K. Padilla, and G. Garcia-Alcocer, “Therapies for prevention and treatment of Alzheimer’s disease,” Biomed. Res. Int., 2016, 2589276 (2016), https://doi.org/10.1155/2016/2589276.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. P. Valdés and B. L. Schneider, “Gene therapy: A promising approach for neuroprotection in Parkinson’s disease?” Front. Neuroanat., 10, 123 (2016), https://doi.org/10.3389/fnana.2016.00123.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. F. Calzi, R. Bellasio, G. Guiso, et al., “Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo,” Eur. J. Pharmacol., 5, No. 338, 185–190 (1997), https://doi.org/10.1016/s0014-2999(97)81947-4.

    Article  Google Scholar 

  23. D. Grosset, A. Antonini, M. Caneci, et al., “Adherence to antiparkinson medication in a multicenter European study,” Mov. Disord., 6, No. 24, 826–832 (2009), https://doi.org/10.1002/mds.22112.

    Article  Google Scholar 

  24. A. Münchau and K. P. Bhatia, “Pharmacological treatment of Parkinson’s disease,” Postgrad. Med. J., 76, No. 10, 602–610 (2000), https://doi.org/10.1136/pmj.76.900.602.

    Article  PubMed  PubMed Central  Google Scholar 

  25. A. Castro-Caldas, P. Delwaide, W. Jost, et al., “The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson’s disease,” Mov. Disord., 21, No. 4, 500–509 (2006), https://doi.org/10.1002/mds.20750.

    Article  PubMed  Google Scholar 

  26. H. Ollat, “Dopaminergic insuffi ciency refl ecting cerebral ageing: value of a dopaminergic agonist, piribedil,” J. Neurol., 239, Suppl. 1, S13–16 (1992), https://doi.org/10.1007/BF00819561.

    Article  PubMed  Google Scholar 

  27. N. Volkow, G. Wang, J. Fowler, et al., “Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging,” Ann. Neurol., 1, 143–147 (1998), https://doi.org/10.1002/ana.410440125.

    Article  Google Scholar 

  28. G. Halliday, R. Barker, and D. Rowe, Non-Dopamine Lesions in Parkinson’s Disease, Oxford Univ. Press (2011).

    Google Scholar 

  29. V. V. Zakharov and A. B. Lokshina, “The use of Pronoran (piribedil) treatment of mild cognitive disorders in elderly patients with cortical ischemia,” Nevrol. Zh., No. 2, 30–35 (2004).

  30. D. Nagaraja and S. Jayashree, “Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment,” Am. J. Psychiatry, 9, 1517–1519 (2001), https://doi.org/10.1176/appi.ajp.158.9.1517.

    Article  Google Scholar 

  31. C. S. Peretti, F. Gierski, and S. Harrois, “Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil,” Psychopharmacology (Berlin), 176, No. 2, 175–181 (2004), https://doi.org/10.1007/s00213-004-1869-8.

    Article  CAS  Google Scholar 

  32. C. Corbe, F. Arnaud, Y. Brault, and C. Janiak-Bolzinger, “Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects,” J. Neurol., 239, 22–27 (1992), https://doi.org/10.1007/BF00819563.

    Article  Google Scholar 

  33. S. Schuck, D. Bentue-Ferrer, D. Kleinermans, et al., “Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers,” Fundam. Clin. Pharmacol., 16, 57–65 (2002), https://doi.org/10.1046/j.1472-8206.2002.00070.x.

    Article  CAS  PubMed  Google Scholar 

  34. V. V. Zakharov, “The all-Russian research program for the epidemiology and treatment of cognitive impairment in the elderly (“Prometheus”),” Nevrol. Zh., No. 11, 27–32 (2006).

    Google Scholar 

  35. N. N. Yakhno, V. V. Zakharov, E. Ya. Strachunskaya, et al., “The of nondementia cognitive impairments in patients with arterial hypertension and cerebral atherosclerosis (results of the Russian FUETE multicenter study),” Nevrol. Zh., No. 4, 49–55 (2012).

  36. O. S. Levin and L. V. Golubeva, “Heterogeneity in moderate cognitive impairment: diagnostic and therapeutic aspects,” Consilium Medicum, No. 2, 106–112 (2006).

  37. O. V. Vorob’eva, Zh. M. Sizova, and L. M. Bogatyreva, “Comparative study of pharmacological correction strategies for moderate cognitive impairment in patients with arterial hypertension,” Nevrol. Neiropsikh. Psikhosom., No. 2, 52–59 (2019), https://doi.org/10.14412/2074-2711-2019-2-52-59.

  38. A. Schrag, A. Sauerbier, and K. R. Chaudhuri, “New clinical trials for nonmotor manifestations of Parkinson’s disease,” Mov. Disord., 30, No. 11, 1490–1504 (2015), https://doi.org/10.1002/mds.26415.

    Article  CAS  PubMed  Google Scholar 

  39. A. A. Pilipovich and V. L. Golubev, “The dopamine receptor agonist piribedil in the treatment of Parkinson’s disease,” Zh. Nevrol. Psikhiatr., No. 6, 83–90 (2017), https://doi.org/10.17116/jnevro20171176183-90.

  40. A. Salva, S. Andrieu, E. Fernandez, et al., “Health and nutrition promotion program for patients with dementia (NutriAlz, cluster randomized trial,” J. Nutr. Health Aging, 15, No. 10, 822–830 (2011), https://doi.org/10.1007/s12603-011-0363-3.

  41. G. S. Vlachos and N. Scarmeas, “Dietary interventions in mild cognitive impairment and dementia,” Dialogues Clin. Neurosci., 21, No. 1, 69–82 (2019), https://doi.org/10.31887/DCNS.2019.21.1/nscarmeas.

  42. R. Malouf and J. Grimley Evans, “Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people,” Cochrane Database Syst. Rev., No. 4, Cd004514 (2008), https://doi.org/10.1002/14651858.CD004514.

    Article  Google Scholar 

  43. N. Farina, D. Llewellyn, M. G. Isaac, and N. Tabet, “Vitamin E for Alzheimer’s dementia and mild cognitive impairment,” Cochrane Database Syst. Rev., No. 1, CD002854 (2017), https://doi.org/10.1002/14651858.CD002854.pub4.

    Article  Google Scholar 

  44. S. Canhada, K. Castro, I. S. Perry, and V. C. Luft, “Omega-3 fatty acids’ supplementation in Alzheimer’s disease: A systematic review,” Nutr. Neurosci., 21, No. 8, 529–538 (2018), https://doi.org/10.1080/1028415X.2017.1321813.

    Article  CAS  PubMed  Google Scholar 

  45. P. Scheltens, J. W. Twisk, R. Blesa, et al., “Efficacy of Souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial,” J. Alzheimers Dis., 31, No. 1, 225–236 (2012), https://doi.org/10.3233/JAD-2012-121189.

    Article  CAS  PubMed  Google Scholar 

  46. P. J. Kamphuis, F. R. Verhey, M. G. Olde Rikkert, et al., “Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer’s disease: secondary analyses from a randomized, controlled trial,” J. Nutr. Health Aging, 15, No. 8, 672–676 (2011), https://doi.org/10.1007/s12603-011-0339-3.

  47. E. G. A. Karssemeijer, J. A. Aaronson, W. J. Bossers, et al., “Positive effects of combined cognitive and physical exercise training on cognitive function in older adults with mild cognitive impairment or dementia: A meta-analysis,” Ageing Res. Rev., 40, 75–83 (2017), https://doi.org/10.1016/j.arr.2017.09.003.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sechenov First Moscow State Medical University (Sechenov University), Russian Ministry of Health, Moscow, Russia

    A. A. Pilipovich & O. V. Vorob’eva

Authors
  1. A. A. Pilipovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. V. Vorob’eva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. A. Pilipovich.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 120, No. 11, Iss. 1, pp. 124–130, November, 2020.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pilipovich, A.A., Vorob’eva, O.V. Mild Cognitive Impairment: Current Aspects of Diagnosis and Treatment. Neurosci Behav Physi 51, 1033–1039 (2021). https://doi.org/10.1007/s11055-021-01162-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-021-01162-7

Keywords

Search

Navigation